RecruitingNon-Small Cell Lung Cancer

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Eligible age

18+ yrs

Accepts

All genders

Locations

29 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Sponsor: AstraZeneca

You may qualify if…

✓ Histologically or cytologically documented non-squamous NSCLC.
✓ Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
✓ Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
✓ Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
✓ Known tumour PD-L1 expression status defined as TC ≥ 50%
✓ At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
✓ ECOG performance status of 0 or 1
✓ Adequate bone marrow reserve and organ function

You may not qualify if…

✕ Prior systemic therapy for advanced/metastatic NSCLC.
✕ Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
✕ History of another primary malignancy within 3 years
✕ Active or prior documented autoimmune or inflammatory disorders (with exceptions)
✕ Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
✕ Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
✕ History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
✕ Has significant pulmonary function compromise, as determined by the investigator